• Is remote exposure to major venous thromboembolism (VTE) risk factor related to lower recurrence? • We analyzed data from the REVERSE study, a cohort of patients with no recent major risk factor.
Essentials
• Is remote exposure to major venous thromboembolism (VTE) risk factor related to lower recurrence? • We analyzed data from the REVERSE study, a cohort of patients with no recent major risk factor.
• We found no association between remote risk factors and the risk of recurrence.
• Patients with remote VTE risk factor should be managed as having had an unprovoked VTE.
Summary. Background: It has been shown that the risk of recurrence of venous thromboembolism (VTE) is significantly lower when provoked by a major risk factor such as surgery or trauma compared with an event that was unprovoked. Objectives: In this study we aimed to assess the association between remote exposure (3-12 months prior to VTE) to major VTE risk factors and the risk of recurrent VTE. Methods: This was a post-hoc analysis of the REVERSE study, a prospective cohort of 646 patients with a first VTE, not provoked by a recent (< 3 months) major risk factor. Results: We found no difference in the recurrence rate in patients with or without remote exposure to major VTE risk factors, including immobilization (hazard-ratio [HR], 1.4; 95% confidence interval, 0.7-
Introduction
The long-term risk of recurrent venous thromboembolism (VTE) is lower when the index event is provoked by a major transient risk factor such as surgery or trauma, as compared with an unprovoked VTE [1, 2] . Patients with a provoked VTE occurring within 3 months of a major transient risk factor may be managed with short-course oral anticoagulant therapy (OAT) (3 months). Indeed, the risk of recurrent VTE following discontinuation of the OAT is low in these patients [3] , probably because the trigger for thrombosis development is no longer present, whereas patients whose thrombus developed despite the absence of an identified trigger are more likely to have recurrence at any time. Although definitions vary according to studies and authors, VTE is generally classified as provoked when it occurs within 3 months after exposure to a major risk factor (e.g. surgery with general anesthetics, immobilization that exceeds 3 days, leg fracture or lower-extremity plaster cast, etc.) [4] . Whether patients exposed to a major risk factor more than 3 months before their index VTE have a lower risk of recurrence and should be managed differently from other patients with unprovoked VTE remains to be determined.
Methods
We used data from the REVERSE (REcurrent VEnous thromboembolism Risk Stratification Evaluation) cohort study, a multicenter international study that was primarily aimed at deriving a clinical prediction rule for recurrent VTE in patients with a first unprovoked VTE [5] . Between October 2001 and March 2006, patients with a first episode of unprovoked VTE were enrolled, and followed over a period of 18 months after they had completed a course of 5-7 months on OAT. Unprovoked VTE was defined as: VTE event in the absence of fracture, plaster cast, immobilization greater than 3 days or a general anesthetic in the last 3 months prior to the VTE occurrence. Patients were included based on an objective diagnosis of deep vein thrombosis (DVT) or pulmonary embolism (PE). Patients were also required to have been treated with a minimum of 5 days of heparin or lowmolecular-weight heparin and OAT with a target intensity of 2.0-3.0, with no recurrence, and were on OAT at the time of inclusion. Patients were excluded if they had a previous unprovoked VTE, were aged < 18 years or had 'known high-risk thrombophilia' (deficiency of protein S, protein C or antithrombin, persistently positive anticardiolipin antibodies [titers > 30 U mL À1 ] or lupus anticoagulant, or combined thrombophilic defects [e.g. homozygous for factor V Leiden or G2010A prothrombin gene mutations, or compound heterozygous]). All patients had their anticoagulant therapy discontinued after 5-7 months, when they were included in the study. At this time, patients underwent baseline screening as well as screening for the presence of any of the 69 previously determined candidate predictors for recurrent VTE. The follow-up period started at discontinuation of the anticoagulant therapy. The participants of the REVERSE study were followed-up in clinic every 6 months and monitored for any signs of a recurrent VTE. We tested the association between recurrent VTE during follow-up and the following risk factors: immobilization (bed rest > 90% of the time for more than 3 days) more than 3 months but less than 1 year before index VTE; surgery under general anesthetic (> 3 to 12 months); leg fracture or lower-extremity plaster cast (> 3 to 12 months); emergency room visit or admission to hospital for decompensated heart failure; or admission to hospital for stroke or myocardial infarction in the past year. Finally, we tested the association between the risk of recurrent VTE and a history of malignancy more than 5 years prior to VTE (patients with a malignancy within 5 years prior to their VTE were excluded from the study). These data were prospectively collected as part of the inclusion visit case report form. The proportion of patients with recurrent VTE during follow-up was determined according to the presence or absence of each of these risk factors. Kaplan-Meier survival curves and hazard ratios (HRs) were used to test for the association between exposure to risk factors and the risk of recurrence during follow-up. The proportional hazard assumption was tested by adding a time-dependent covariate to the Cox regression model.
Results and discussion
In this cohort study, 646 patients with a first unprovoked VTE were recruited from 2002 to 2006. There were 332 men and 314 women with a mean age of 53 (standard deviation [SD], 17) years and BMI of 29 (SD 7) kg m À2 .
VTE localization was as follows: 194 PE, 339 proximal DVT and 113 with both PE and DVT. After a mean follow-up duration of 18 months, 91 patients had an adjudicated recurrent VTE. There was no difference in the risk of recurrent VTE in patients with or without remote exposure to major risk factors, as displayed in Table 1 . Of the 50 patients who underwent surgery in the year prior to but more than 3 months before the index VTE, five (10%) had a recurrent VTE. Survival analysis showed no association with the risk of recurrent VTE (HR, 0.8; 95% confidence interval [CI], 0.3-1.9]). The Kaplan-Meier survival curve is displayed in Fig. 1 . There were two patients with congestive heart failure, three patients with a stroke and three patients with a myocardial infarction within the last year who were enrolled, none of whom had a recurrent VTE. A total of 15 patients had a remote (> 5 years) history of malignancy, one of whom (6.7%) had a recurrent VTE (HR, 0.5; 95% CI, 0.1-3.5). Adjustment for age, gender or body mass index in Cox regression multivariate analyses did not alter the results (data not shown).
We found no association between remote (> 3 to < 12 months) major VTE risk factors at the time of index VTE and the risk of recurrent VTE after discontinuation of OAT. Current guidelines suggest long-term anticoagulation in patients with a first unprovoked VTE [3] . This is often frustrating for patients and physicians, and efforts have been made to identify patients at low risk of recurrent VTE who may discontinue anticoagulation after a short course of OAT. A strong risk factor temporarily leads to a hypercoagulable state, but once corrected should leave the patient with a risk of recurrent VTE that is similar to that of the general population [1] . However, the period of time during which patients remain at high risk of VTE after a provoking factor might vary according to the type of provoking factor or to patients' characteristics. For instance, in a cohort study of patients undergoing orthopedic surgery, the peak incidence of symptomatic DVT was at 17 days for total hip arthroplasty and 7 days for knee arthroplasty [6] . In clinical practice, many patients do report exposure to important VTE risk factors outside of the time window traditionally used to define a provoked VTE. Our results suggest that this should not be reassuring for clinicians given that they have a risk of VTE similar to patients with completely unprovoked VTE. Our results also support the current definitions and the up to 3 months' time-frame used in the recent ISTH guidance on categorization of provoked and unprovoked VTE [7] . It is important to note the limitations of our study. Details on the remote major risk factors (e.g. exact type and duration of surgery; degree of, duration and reason for immobilization; detailed information on remote cancer; etc.) were not captured. The limited number of patients in each category also limits the interpretation of the results.
In summary, exposure to an important risk factor more than 3 months before the index VTE episode was not associated with a lower risk of recurrence during followup. Patients with remote exposure to major risk factors at the time of a first VTE should probably not be managed differently from patients with no identified risk factors or unprovoked VTE.
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